

# Atherosclerosis in Primary Antiphospholipid Syndrome: Summary of Clinical and Pathogenic Evidence

Ames PRJ<sup>1\*</sup>, Lopez LR<sup>2</sup>, Matsuura E<sup>3</sup> and Margarita A<sup>4</sup>

<sup>1</sup>William Harvey Research Institute, Queen Mary University London, London, UK

<sup>2</sup>Department of medical, Director Corgenix, Inc., Broomfield, Colorado, USA

<sup>3</sup>Department of Cell Chemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

<sup>4</sup>Angiology Section, Multimedica, Naples, Italy

## Abstract

The Antiphospholipid Syndrome (APS) was described in the early '80s as a combination of thrombosis, thrombocytopenia and recurrent miscarriages associated with persistent high titers of Antiphospholipid Antibodies (aPL). In subsequent years, it became apparent that aPL were also associated with premature atherosclerosis in Systemic Lupus Erythematosus (SLE) and more recently in primary APS (PAPS). The studies exploring atherosclerosis in PAPS were heterogeneous in conception and size, but overall, provided enough evidence that Intima Media Thickness (IMT) of carotid arteries and endothelial function are abnormal in PAPS. In keeping with the general view that atherosclerosis is a low grade inflammatory and "auto"immune disorder characterised by oxidative and nitrate stress, several studies have confirmed similar findings in PAPS, though a specific relation with the severity of atherosclerosis is lacking. Given its development at an earlier age than average, atherosclerosis should be taken into account in the overall management of PAPS patients as it may significantly add to the vascular risk.

**Keywords:** Atherosclerosis; Intima media thickness; Antiphospholipid syndrome

## Introduction

The occurrence of arterial or venous thrombosis and recurrent miscarriages in the presence and persistence of Antiphospholipid Antibodies (aPL) detected by immunoassays or clotting tests defines the Antiphospholipid Syndrome (APS) [1]. Early observations suggesting that aPL contributed to atherosclerosis in Systemic Lupus Erythematosus (SLE) lead to testing the atherosclerosis hypothesis in primary APS (PAPS) through the measurement of Intima Media Thickness (IMT) in large enough PAPS series [2-11]. This review will survey the pathways associated with premature atherosclerosis in PAPS as they temporally appeared in the scientific literature, and will discuss how these reports support the concept of atherosclerosis as a low grade inflammatory and immune process.

## Evidence for Atherosclerosis in PAPS

### Atherosclerosis detected as intima media thickening

The measurement of IMT via high-resolution ultrasonography of carotid arteries is a surrogate but established method to identify patients at early risk of atherosclerosis that has been employed to detect sub-clinical atherosclerosis in several PAPS series [3]. Two of these series did not find intima-media thickening in PAPS: in one study, IMT and plaque prevalence were similar in 45 PAPS patients with deep vein thrombosis and in non-APS thrombotic controls matched by age, sex and other vascular risk factors. Having examined the abdominal aorta, the carotid and femoral arteries the authors concluded that atherosclerosis was not a feature of their PAPS cohort [4]. Another survey of PAPS, SLE related APS and normal controls revealed similar IMT across groups though there was a higher plaque frequency in SLE related APS (37.5%) vs. PAPS (8%) [5]. Similarly plaques were detected in 14% of SLE related APS and in 9% of PAPS with no differences in IMT though plaques were more frequent in patients with prior arterial and venous thromboses [6].

On the other hand, 3 reports of PAPS patients showed greater IMT with a greater prevalence of plaques (21%) compared to an equal

number of age and sex matched non-thrombotic controls (3%) [7-10]. These studies have some limitations in that PAPS patients, by definition, are characterised by persistence of aPL and thrombosis, and any such study should include both healthy (normal) and thrombotic controls with persistence of the thrombotic risk factor. With this in mind, we provided conclusive evidence for premature atherosclerosis defined as increased IMT in PAPS patients over 40 years of age compared to younger PAPS patients, and to thrombotic and non-thrombotic controls matched by age and sex. Interestingly, diastolic blood pressure was an independent predictor of the IMT of the carotid artery [11]. Table 1 summarises the IMT measurements and plaque prevalence of the above mentioned studies while Table 2 shows the distribution of IMT by age tertiles from our study [11].

### Atherosclerosis detected as arterial stenosis and heart valve disease

Stenosis of several arteries may be viewed as an athero-thrombotic complication in PAPS [12]. Renal artery stenosis may have further implication with regards to increased arterial blood pressure that may adversely affect atherosclerotic cardiovascular disease [13]. In addition, thickening of heart valves in PAPS may bear atherosclerotic significance. A trans-oesophageal ultrasound study on 31 patients revealed functional and structural defects in the mitral valve of 84% of PAPS patients examined; valve lesions were more common in subjects with high titres of IgG anticardiolipin (aCL) and a history of arterial

\*Corresponding author: Paul RJ Ames, William Harvey Research Institute, Queen Mary University London, London, UK, Tel: +407816225826; E-mail: [paxmes@aol.com](mailto:paxmes@aol.com)

Received January 21, 2014; Accepted March 20, 2014; Published March 31, 2014

Citation: Ames PRJ, Lopez LR, Matsuura E, Margarita A (2014) Atherosclerosis in Primary Antiphospholipid Syndrome: Summary of Clinical and Pathogenic Evidence. J Clin Exp Cardiol 5: 293. doi:10.4172/2155-9880.1000293

Copyright: © 2014 Ames PRJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Table 1:** Intima media thickness of carotid arteries in patients with primary antiphospholipid syndrome.

Reference No	4	5	6	7	8	9	10	11
Patients No	45	25	58	28	28	77	58	49
Mean age	47	38.6		40	NR	46	29	37
M/F	15/30			16-Dec	16-Dec	0/77	1/4	18/31
IMT CC (mm)		0.7		2.6	0.68	0.75	0.71	0.48
Plaque %	35.6	8	9		53		21	11
Thrombotic Controls No	40				26			49
Mean Age	47				NR			37
M/F	15/25							18/31
IMT CC (mm)					0.58			0.44
Plaque %	35							5.8
Healthy Controls No		40	89	28	38	77	58	49
Mean age		42		41	NR	47	29	37
M/F				16-Dec		0/77	4-Jan	18/31
IMT CC (mm)		0.61		1.2	0.58	0.64	0.59	0.41
Plaque %		15	?				3	5.8

**Abbreviations:** IMT: Intima Media Thickness; CC: Common Carotid Artery; NR: Not Reported. Study No 8 included as controls a mixture of patients with coronary artery disease and healthy subjects; Study No 10 included patients with systemic lupus erythematosus. Study No 7 used different parameters for IMT measurement.

**Table 2:** Intima-media thickness of carotid artery segments by age tertiles from Ames et al. [11].

	Intima-media thickness of common carotid (mm)			P
	CTR	IT	PAPS	
1 <sup>st</sup> tertile	0.347 ± 0.030	0.386 ± 0.064	0.406 ± 0.090	0.05
2 <sup>nd</sup> tertile	0.384 ± 0.047	0.405 ± 0.055	0.468 ± 0.088	0
3 <sup>rd</sup> tertile	0.496 ± 0.074	0.528 ± 0.085	0.581 ± 0.119	0.03
	Intima-media thickness of carotid bifurcation (mm)			
1 <sup>st</sup> tertile	0.412 ± 0.078	0.479 ± 0.083	0.438 ± 0.081	0.15
2 <sup>nd</sup> tertile	0.446 ± 0.065	0.504 ± 0.085	0.529 ± 0.094	0.02
3 <sup>rd</sup> tertile	0.557 ± 0.113	0.564 ± 0.093	0.693 ± 0.171	0
	Intima-media thickness of internal carotid (mm)			
1 <sup>st</sup> tertile	0.320 ± 0.056	0.368 ± 0.091	0.366 ± 0.086	0.22
2 <sup>nd</sup> tertile	0.374 ± 0.083	0.375 ± 0.061	0.460 ± 0.076	0
3 <sup>rd</sup> tertile	0.444 ± 0.086	0.480 ± 0.077	0.546 ± 0.112	0.01

**Abbreviations:** CTR: Healthy Controls; IT: Inherited Thrombophilia; PAPS: Primary Antiphospholipid Syndrome

**1st tertile:** 16 patients (10M, 6F), mean age 26 ± 4.4 years

**2nd tertile:** 16 patients (10M, 6F), mean age 36 ± 2.7 years

**3rd tertile:** 17 patients (11M, 6F), mean age 49 ± 8.5 years

thrombosis, particularly cerebrovascular events [14]. Another series on 40 patients revealed mitral valve thickening in 82% of PAPS patients in strong association with IgG aCL titre with significant progression of valve lesions at a five year of follow-up [15,16]. These findings may have strong repercussions at the time of heart valve surgery where 50% of patients may develop complications with a mortality rate of 12.5% [17].

### Atherosclerosis and endothelial dysfunction

Endothelial dysfunction may develop very early in the course of atherosclerosis and may match early IMT changes in pathophysiologic significance. An abnormal ankle-brachial-index was more common in PAPS (19%) than in healthy controls group (4%) though these findings were not corrected for confounders such as hypertension, obesity and hypercholesterolaemia [18]. Flow mediated vasodilatation was consistently lower in PAPS than in controls particularly in patients with arterial disease [8,9,19-22].

### Atherosclerosis findings on histology

The pattern of vascular involvement in PAPS is one of histologic intimal/medial hyperplasia and radiologic fibromuscular hyperplasia, but it is unclear whether this represents a distinct vasculopathy [23-25].

## Atherogenic Pathways in Paps

### Traditional and non-traditional risk factors for atherosclerosis

Hypertension, hypercholesterolemia, diabetes mellitus, obesity, smoking, sedentary life style and family history are traditional risk factors for atherosclerosis identified by the Framingham Heart Study [26]. While some of these factors may be operative in APS related to SLE, their role in primary APS seem to be less dominant [2]. Less than 5% of our PAPS patients have any of these risk factors, others may have up to 36% traditional risk factors while the use of matching controls with similar risk factors still identified aPL as an independent contributor to atherosclerosis. In another survey at least 50% of PAPS patients had one traditional risk factor [1,15,16].

### Haemostatic variables and atherosclerosis

Plasma Fibrinogen (FNG) and von Willebrand Factor (vWF) have been identified as risk factors for thrombosis and atherosclerosis [27,28]. An early study revealed that these variables were differentially associated with arterial and venous occlusions in PAPS regardless of sex [29]. More recently, plasma FNG was identified as an independent predictor of IMT of carotid arteries in PAPS [10,30]. Moreover PAPS patients presented coagulation activation, depressed fibrinolysis

and elevated D-dimers, a marker of heightened fibrin turnover [31]. Elevated Plasminogen Activator Inhibitor (PAI), a marker of depressed fibrinolysis and a risk factor for atherosclerosis, correlated with IMT of carotid arteries and to heightened Factor XIII activity that tightens the fibrin clot making it more resistant to plasmin lysis [30,32,33]. Therefore PAPS patients are in a state of accelerated fibrin turnover and fibrin deposition on the vessel wall that is a recognized early phenomenon in atherogenesis [34].

### **Oxidative stress, oxidative low density lipoprotein ligands and atherosclerosis**

Paraoxonase (PON) is an enzyme present in the arterial wall and associated to HDL in plasma [35,36]. Reduced PON activity (PONA) contributes to lipid peroxidation, a major process in atherosclerosis [37]. Specific by-products of lipid peroxidation induce transcriptional activation of the genes that promote vascular adhesion molecules and monocyte chemo-attractant proteins shifting the endothelium towards a pro-adhesive and pro-thrombotic phenotype [38]. PAPS is characterised by reduced PONA, greater IMT and enhanced lipid peroxidation [9,39]. The former and the latter were respectively inversely and positively correlated to aPL titres, all contributing to the athero-thrombotic tendency of PAPS via the over-generation of isoprostanes linked to platelet activation and to heightened diastolic blood pressure [40].

Low-Density Lipoproteins (LDL) contain phospholipids, free cholesterol, cholesteryl esters, triglycerides and apolipoprotein B (apoB) that are all susceptible to oxidation [41]. A weak in vitro oxidation induced by copper generates Cu<sup>2+</sup>-oxLDL that interacts with lysine residues on  $\beta$ 2GPI. This interaction is initially electrostatic and reversible but later progresses to a stable bond involving a Schiff base formation [42]. In this process,  $\beta$ 2GPI neutralizes the negative charges generated by Cu<sup>2+</sup>-oxLDL undertaking a possible anti-oxidant and anti-inflammatory effect alongside its anticoagulant and anti-apoptotic properties [43]. Since oxLDL stimulates the release of several soluble inflammatory and adhesion molecules, induces a pro-thrombotic endothelial surface and promotes inflammation by attracting monocytes and T-lymphocytes to the arterial intima. The possibility that  $\beta$ 2GPI might blunt all these activities is highly attractive. On the other hand, given the strong immunogenic properties of oxLDL and  $\beta$ 2GPI, it is possible that autoantibodies against  $\beta$ 2GPI-oxLDL may hamper these positive effects of  $\beta$ 2GPI [44]. From the clinical standpoint, IgG anti- $\beta$ 2GPI-oxLig1 independently predicted intima media thickness of different carotid segments and was inversely related to PONA highlighting an important role of oxidative/antioxidant systems in PAPS related atherogenesis [45].

### **Monocytes/macrophages and atherosclerosis**

Monocytes/macrophages have receptors for LDL that should prevent lipid over-loading. Native LDL is taken up by specific LDL receptor whereas oxLDL is taken up by scavenger receptors [46]. The presence of  $\beta$ 2GPI and IgG  $\beta$ 2GPI auto-antibodies increases the macrophage uptake of I131-Cu<sup>2+</sup>-oxLDL in keeping with a pro-atherogenic role of IgG anti- $\beta$ 2GPI antibodies [47]. The uptake of the immune complexes is likely mediated by macrophage Fc $\gamma$  receptors rather than scavenger receptors. During the uptake process, circulating monocytes may have adhered to endothelial cells and started their migration into the intima of the arterial wall where they contribute to the intima media thickening typical of atherosclerosis alongside other cellular components.

### **Soluble CD14, neopterin and atherosclerosis**

The expression of CD14 on the membranes of monocytes increases with the differentiation of monocytes into macrophages. Shedding of CD14 induced by serine proteases leads to a soluble CD14 (sCD14) present in plasma [48]. Neopterin (NPT) is produced in large amounts by human monocytes/macrophages upon stimulation with the cytokine interferon- $\gamma$  released by activated T-lymphocytes [49]. Whereas mCD14 complex is expressed on macrophages and endothelial cells within the atherosclerotic plaque, plasma sCD14 shows no relation with stable coronary artery disease or carotid IMT [50-54]. NPT is associated with different stages of peripheral vascular disease and with carotid atherosclerosis, and predicts coronary artery disease progression [55-57]. In support of a role for monocytes/macrophages in the vascular pathogenesis of PAPS, serum levels of sCD14 and neopterin were elevated in thrombotic PAPS compared to thrombotic and normal controls. Moreover in PAPS patients the number of thrombotic events predicted NPT whereas arterial disease predicted NPT and sCD14 [58].

### **Antibodies against high density lipoprotein and atherosclerosis**

High-Density Lipoprotein (HDL) protects against atherosclerosis by inhibiting LDL oxidation by way of its PONA content [36]. Apolipoprotein A-I (ApoA-I), the major protein component of HDL stabilizes the molecule and protects humans from cholesterol accumulation in tissues [59]. In this regard, ApoA-I possesses nearly identical information as HDL in terms of risk prediction for future cardiovascular disease [59]. Any interference with HDL components could thus compromise the protective role of HDL. In the context of autoimmune diseases, HDL represents a likely target for auto-reactivity. Elevated levels of anti-HDL have been reported in PAPS in association with decreased PONA and HDL [60,61]. Moreover low levels of Apo A and HDL inversely related to C-Reactive Protein (CRP) in keeping with an anti-inflammatory activity of these lipoproteins in PAPS [61].

### **Inflammation, nitrate stress and atherosclerosis**

CRP, the first acute-phase protein identified, is a strong predictor of first clinical events, recurrent events, coronary heart disease endpoints and ischaemic stroke [62]. Serum amyloid A (SAA) is an apolipoprotein that circulates in plasma in association with HDL [63-65]. Several observational and prospective studies show that SAA parallels CRP with regards to cardiovascular disease prediction, although the absolute level of risk is generally much smaller [66-69]. Plasma concentrations of CRP and (SAA) are elevated in patients with thrombotic PAPS compared to thrombotic and normal controls and suggest that PAPS is a low grade inflammatory disease. Moreover, the number of thrombotic events was an independent predictor of SAA [58]. Conversely, CRP was also an independent predictor of crude plasma Nitro-Tyrosine (NT), a marker of nitrate stress, implying that low grade inflammation and nitration may be related phenomena in thrombotic PAPS [70]. Nitration of plasma proteins is partially accomplished by peroxynitrite anion (ONOO<sup>-</sup>) that results from the interaction of superoxide anion (O<sub>2</sub><sup>-</sup>) released by monocytes, neutrophils and endothelial cells with nitric oxide (NO<sub>2</sub>) produced by endothelial cells [71]. The oxidative inactivation of NO by superoxide anion (O<sub>2</sub><sup>-</sup>) is the prevalent mechanisms leading to decreased bioavailability of NO, an early phenomenon in atherosclerosis, associated with impaired vasomotor tone and increased platelet reactivity [72]. PAPS patients, particularly patients with arterial disease, show decreased mean plasma nitrite (NO<sub>2</sub><sup>-</sup>) concentration [70].

## Conclusion

### Management of PAPS related atherosclerosis

At present we do not know how to manage PAPS related atherosclerosis. Control of modifiable risk factors such as the lipid profile is intuitive. However the progression of heart valve lesions in PAPS is worrying and warrants clinical intervention [16]. Treatment may be directed at managing the effects of aPL antibodies or at decreasing aPL titres. Given their positive effects on the immune system, on the vascular endothelium and on PONA (reviewed in [73]), statins may be suitable candidates within the context of a clinical trial. Indeed, an in vitro study showed that pravastatin was effecting at reverting the pro-adhesive and pro-thrombotic phenotype induced by aPL on endothelial cells, and a one month interventional trial with fluvastatin restored monocyte function in patients with APS [74,75]. Probucol ameliorated coagulation activation and lipid peroxidation in PAPS [76]. Aspirin may be useful for the primary prevention of arterial events in aPL positive subjects that may go on to develop atherosclerosis [77]. Anti-CD20 accomplished lowering of aPL titers in some PAPS patients but not others [78].

### Concluding remarks

Atherosclerosis is a clinical manifestation that further qualifies PAPS as a systemic vascular disease. PAPS is a relatively rare disorder and any interventional trial would require homogenous populations in a multicentre fashion to evaluate suitability of anti-atherosclerotic drugs and dosages.

### Acknowledgements

The work in this review was supported by www.SenitFoundation.co.uk, Scotland, UK and by www.FondazioneAPS.com, Italy.

### References

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost* 4: 295-306.
2. Roman MJ, Salmon JE, Sobel R, Lockshin MD, Sammaritano L et al (2001). Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid syndrome. *Am J Cardiol* 87: 663-666.
3. Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, et al. (1991) Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. *Am J Epidemiol* 134: 250-256.
4. Bilora F, Boccioletti V, Girolami B, Zanon E, Armani M, et al. (2002) Are antiphospholipid antibodies an independent risk factor for atherosclerosis? *Clin Appl Thromb Hemost* 8: 103-113.
5. Jiménez S, García-Criado MA, Tàssies D, Reverter JC, Cervera R, et al. (2005) Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. *Rheumatology (Oxford)* 44: 756-761.
6. Reshetniak TM, Seredavkina nV, Mach ES, Aleksandrova EN, Novikov AA, et al. (2008) [Subclinical and clinical manifestations of atherosclerosis in antiphospholipid syndrome]. *Ter Arkh* 80: 60-67.
7. Medina G, Casaos D, Jara LJ, Vera-Lastra O, Fuentes M, et al. (2003) Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. *Ann Rheum Dis* 62: 607-610.
8. Soltész P, Der H, Veres K, Laczik R, Sipka S, et al. (2008) Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. *Rheumatology (Oxford)* 47: 1628-1634.
9. Charakida M, Besler C, Batuca JR, Sangle S, Marques S, et al. (2009) Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. *JAMA* 302: 1210-1217.
10. Belizna CC1, Richard V, Primard E, Kerleau JM, Cailleux N, et al. (2008) Early

atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding. *Semin Arthritis Rheum* 37: 373-380.

11. Ames PR, Antinolfi I, Scenna G, Gaeta G, Margaglione M, et al. (2009) Atherosclerosis in thrombotic primary antiphospholipid syndrome. *J Thromb Haemost* 7: 537-542.
12. Ben-Ami D Bar-Meir E, Shoenfeld Y (2006) Stenosis in antiphospholipid syndrome: a new finding with clinical implications. *Lupus* 15: 466-472.
13. Christodoulou C, Sangle S, D'Cruz DP (2007) Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome. *Rheumatology (Oxford)* 46: 907-910.
14. Erdogan D, Goren MT, Diz-Kucukkaya R, Inanc M (2005) Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. *Stroke* 36: 592-596.
15. Turiel M, Muzzupappa S, Gottardi B, Crema C, Sarzi-Puttini P et al (2000). Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. *Lupus* 9: 406-412.
16. Turiel M, Sarzi-Puttini P, Peretti R, Bonizzato S, Muzzupappa S, et al. (2005) Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. *Am J Cardiol* 96: 574-579.
17. Erdozain JG, Ruiz-Iratorza G, Segura MI, Amigo MC, Espinosa G, et al. (2012) Cardiac valve replacement in patients with antiphospholipid syndrome. *Arthritis Care Res (Hoboken)* 64: 1256-1260.
18. Barón MA, Khamashta MA, Hughes GR, D'Cruz DP (2005) Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data. *Ann Rheum Dis* 64: 144-146.
19. Stalc M, Poredos P, Peternel P, Tomsic M, Sebestjen M, et al. (2006) Endothelial function is impaired in patients with primary antiphospholipid syndrome. *Thromb Res* 118: 455-461.
20. Bilora F, Sartori MT, Zanon E, Campagnolo E, Arzenton M, et al. (2009) Flow-mediated arterial dilation in primary antiphospholipid syndrome. *Angiology* 60: 104-107.
21. Cugno M, Borghi MO, Lonati LM, Ghiadoni L, Gerosa M, et al. (2010) Patients with antiphospholipid syndrome display endothelial perturbation. *J Autoimmun* 34: 105-110.
22. Mercanoglu F, Erdogan D, Oflaz H, Kücükaya R, Selcukbiricik F, et al. (2004) Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. *Int J Clin Pract* 58: 1003-1007.
23. Hughson MD, McCarty GA, Brumback RA (1995) Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. *Hum Pathol* 26: 716-724.
24. Patel Y, St John A, McHugh NJ (2000) Antiphospholipid syndrome with proliferative vasculopathy and bowel infarction. *Rheumatology (Oxford)* 39: 108-110.
25. Vlachoyiannopoulos PG, Samarkos M (2004) Peripheral vascular disease in antiphospholipid syndrome. *Thromb Res* 114: 509-519.
26. Hemann BA, Bimson WF, Taylor AJ (2007) The Framingham Risk Score: an appraisal of its benefits and limitations. *Am Heart Hosp J* 5: 91-96.
27. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB (1987) Fibrinogen and risk of cardiovascular disease. The Framingham Study. *JAMA* 258: 1183-1186.
28. Welin L, Svärdsudd K, Wilhelmsen L, Larsson B, Tibblin G (1987) Analysis of risk factors for stroke in a cohort of men born in 1913. *N Engl J Med* 317: 521-526.
29. Ames PR, Pyke S, Iannaccone L, Brancaccio V (1995) Antiphospholipid antibodies, haemostatic variables and thrombosis--a survey of 144 patients. *Thromb Haemost* 73: 768-773.
30. Ames PRJ, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L et al (2002). Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. *Lupus* 11: 208-214.
31. Ames PRJ, Tommasino C, Iannaccone L, Brillante M, Cimino R et al (1996). Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies--a crucial role for acquired free protein S deficiency. *Thromb Haemost* 76: 190-194.

32. Vaughan DE (2005) PAI-1 and atherothrombosis. *J Thromb Haemost* 3: 1879-1883.
33. Ames PR, Iannaccone L, Alves JD, Margarita A, Lopez LR, et al. (2005) Factor XIII in primary antiphospholipid syndrome. *J Rheumatol* 32: 1058-1062.
34. Ariëns RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ (2002) Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. *Blood* 100: 743-754.
35. Mackness B, Hunt R, Durrington PN, Mackness MI (1997) Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. *Arterioscler Thromb Vasc Biol* 17: 1233-1238.
36. Mackness MI, Arrol S, Abbott C, Durrington PN (1993) Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. *Atherosclerosis* 104: 129-135.
37. Thomson MJ, Puntmann V, Kaski JC (2007) Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment? *Cardiovasc Drugs Ther* 21: 195-210.
38. Gloire G, Legrand-Poels S, Piette J (2006) NF-kappaB activation by reactive oxygen species: fifteen years later. *Biochem Pharmacol* 72: 1493-1505.
39. Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J et al (2002). Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. *Arthritis Rheum* 46: 2686-2694.
40. Martinuzzo ME, Forastiero RR, Kordich L, Carreras LO (2001). Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies. *Br J Haematol* 114: 845-851.
41. Esterbauer H, Jürgens G, Quehenberger O, Koller E (1987) Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. *J Lipid Res* 28: 495-509.
42. Kobayashi K1, Kishi M, Atsumi T, Bertolaccini ML, Makino H, et al. (2003) Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. *J Lipid Res* 44: 716-726.
43. Passam FH, Giannakopoulos B, Mirarabshahi P, Krilis SA (2011) Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I. *J Thromb Haemost* 9 Suppl 1: 275-282.
44. Tsimikas S (2006) Oxidized low-density lipoprotein biomarkers in atherosclerosis. *Curr Atheroscler Rep* 8: 55-61.
45. Ames PRJ, Delgado Alves J, Lopez LR, Gentile F, Margarita A et al (2006). Antibodies against beta2-glycoprotein I complexed with an oxidised lipoprotein relate to intima thickening of carotid arteries in primary antiphospholipid syndrome. *Clin Dev Immunol* 13: 1-9.
46. Brown MS, Goldstein JL (1985) Scavenger cell receptor shared. *Nature* 316: 680-681.
47. Liu Q, Kobayashi K, Furukawa J, Inagaki J, Sakairi N, et al. (2002) Omega-carboxyl variants of 7-ketocholesterol esters are ligands for beta(2)-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. *J Lipid Res* 43: 1486-1495.
48. Arroyo-Espiguero R, Avanzas P, Jeffery S, Kaski JC (2004) CD14 and toll-like receptor 4: a link between infection and acute coronary events? *Heart* 90: 983-988.
49. De Rosa S, Cirillo P, Pacileo M, Petrillo G, D'Ascoli GL, et al. (2011) Neopterin: from forgotten biomarker to leading actor in cardiovascular pathophysiology. *Curr Vasc Pharmacol* 9: 188-199.
50. Morange PE, Tiret L, Saut N, Luc G, Arveiler D, et al. (2004) TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study. *Eur J Hum Genet* 12: 1041-1049.
51. Edfeldt K1, Swedenborg J, Hansson GK, Yan ZQ (2002) Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. *Circulation* 105: 1158-1161.
52. Koenig W, Khuseynova N, Hoffmann MM, März W, Fröhlich M, et al. (2002) CD14 C(-260)-->T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease. *J Am Coll Cardiol* 40: 34-42.
53. Amar J, Ruidavets JB, Bal Dit Sollier C, Bongard V, Boccalon H, et al. (2003) Soluble CD14 and aortic stiffness in a population-based study. *J Hypertens* 21: 1869-1877.
54. Pu H, Yin J, Wu Y, Zhang D, Wang Y, et al. (2013) The association between CD14 gene C-260T polymorphism and coronary heart disease risk: a meta-analysis. *Mol Biol Rep* 40: 4001-4008.
55. Tatzber F, Rabl H, Koriska K, Erhart U, Puhl H, et al. (1991) Elevated serum neopterin levels in atherosclerosis. *Atherosclerosis* 89: 203-208.
56. Weiss G, Willeit J, Kiechl S, Fuchs D, Jarosch E, et al. (1994) Increased concentrations of neopterin in carotid atherosclerosis. *Atherosclerosis* 106: 263-271.
57. Avanzas P, Arroyo-Espiguero R, Quiles J, Roy D, Kaski JC (2005) Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. *Eur Heart J* 26: 457-463.
58. Ames PR, Antinolfi I, Ciampa A, Batuca J, Scenna G, et al. (2008) Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease? *Rheumatology (Oxford)* 47: 1832-1837.
59. Khuseynova N, Koenig W (2006) Apolipoprotein A-I and risk for cardiovascular diseases. *Curr Atheroscler Rep* 8: 365-373.
60. Batuca JR, Ames PR, Amaral M, Favas C, Isenberg DA, et al. (2009) Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. *Rheumatology (Oxford)* 48: 26-31.
61. Ames PRJ, Matsuura E, Batuca JR, Ciampa A, Lopez RL et al (2010). High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome. *Lupus* 19: 711-716.
62. Peters SA, Visseren FL, Grobbee DE (2013) Biomarkers. Screening for C-reactive protein in CVD prediction. *Nat Rev Cardiol* 10: 12-14.
63. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, et al. (1986) Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. *J Biol Chem* 261: 9644-9651.
64. de Beer MC, Yuan T, Kindy MS, Asztalos BF, Roheim PS, et al. (1995) Characterization of constitutive human serum amyloid A protein (SAA4) as an apolipoprotein. *J Lipid Res* 36: 526-534.
65. Whitehead AS, de Beer MC, Steel DM, Rits M, Lelias JM et al (1992). Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. *J Biol Chem* 267: 3862-3867.
66. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T (2001) The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease--baseline findings of the PAIS project. *Atherosclerosis* 156: 451-456.
67. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moya LA et al (1998). Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. *Circulation* 98: 839- 844.
68. Erren M, Reinecke H, Junker R, Fobker M, Schulte H, et al. (1999) Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. *Arterioscler Thromb Vasc Biol* 19: 2355-2363.
69. Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, et al. (1994) Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. *J Exp Med* 180: 203-209.
70. Ames PR, Batuca JR, Ciampa A, Iannaccone L, Delgado Alves J (2010) Clinical relevance of nitric oxide metabolites and nitrate stress in thrombotic primary antiphospholipid syndrome. *J Rheumatol* 37: 2523-2530.
71. Pryor WA, Squadrito GL (1995) The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. *Am J Physiol* 268: L699-722.
72. Elahi MM, Naseem KM, Matata BM (2007) Nitric oxide in blood. The nitrosative-oxidative disequilibrium hypothesis on the pathogenesis of cardiovascular disease. *FEBS J* 274: 906-923.
73. Blum A, Shamburek R (2009) The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. *Atherosclerosis* 203: 325-330.

74. Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G, et al. (2001) Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. *Arthritis Rheum* 44: 2870-2878.
75. López-Pedraza C, Ruiz-Limón P, Aguirre MÁ, Barbarroja N, Pérez-Sánchez C, et al. (2011) Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. *Ann Rheum Dis* 70: 675-682.
76. Ames PR, Tommasino C, Alves J, Morrow JD, Iannaccone L, et al. (2000) Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study. *Lupus* 9: 688-695.
77. Arnaud L, Mathian A2, Ruffatti A3, Erkan D4, Tektonidou M5, et al. (2014) Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. *Autoimmun Rev* 13: 281-291.
78. Khattri S, Zandman-Goddard G, Peeva E (2012) B-cell directed therapies in antiphospholipid antibody syndrome--new directions based on murine and human data. *Autoimmun Rev* 11: 717-722.

**Citation:** Ames PRJ, Lopez LR, Matsuura E, Margarita A (2014) Atherosclerosis in Primary Antiphospholipid Syndrome: Summary of Clinical and Pathogenic Evidence. *J Clin Exp Cardiol* 5: 293. doi:[10.4172/2155-9880.1000293](https://doi.org/10.4172/2155-9880.1000293)

This article was originally published in a special issue, **Atherosclerosis Vascular disease-2<sup>nd</sup> Edition** handled by Editor(s). Dr. Zhonghua, Sun Department of Imaging and Applied Physics Curtin University, Australia